PriceTargets.com logo

Cogent Biosciences - COGT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $14.83
  • Forecasted Upside: 63.36%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$9.08 As of 11/20/2024 01:00 AM ET
▲ +0.02 (0.22%)

This chart shows the closing price for COGT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cogent Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for COGT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COGT

Analyst Price Target is $14.83
▲ +63.36% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Cogent Biosciences in the last 3 months. The average price target is $14.83, with a high forecast of $21.00 and a low forecast of $10.00. The average price target represents a 63.36% upside from the last price of $9.08.

This chart shows the closing price for COGT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 contributing investment analysts is to moderate buy stock in Cogent Biosciences. This rating has held steady since November 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$19.00 ➝ $21.00
11/13/2024Needham & Company LLCLower TargetBuy ➝ Buy$16.00 ➝ $15.00
11/12/2024WedbushReiterated RatingNeutral$11.00
11/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
10/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
9/24/2024CitigroupBoost TargetBuy ➝ Buy$13.00 ➝ $15.00
9/5/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$8.00 ➝ $10.00
9/3/2024WedbushReiterated RatingNeutral$10.00 ➝ $11.00
9/3/2024HC WainwrightLower TargetBuy ➝ Buy$19.00 ➝ $17.00
8/7/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$22.00 ➝ $19.00
8/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
8/6/2024WedbushReiterated RatingNeutral$10.00
6/27/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
6/17/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
6/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
5/24/2024WedbushReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$19.00
5/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00
2/27/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$18.00 ➝ $20.00
2/26/2024CitigroupBoost TargetBuy ➝ Buy$11.00 ➝ $13.00
2/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$18.00
2/26/2024Robert W. BairdReiterated RatingOutperform ➝ Neutral$14.00 ➝ $8.00
2/23/2024WedbushBoost TargetNeutral ➝ Neutral$5.00 ➝ $10.00
2/22/2024Leerink PartnrsReiterated RatingOutperform
2/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$15.00
2/8/2024CitigroupInitiated CoverageBuy$11.00
1/9/2024WedbushReiterated RatingNeutral
12/15/2023HC WainwrightLower TargetBuy ➝ Buy$27.00 ➝ $13.00
12/11/2023WedbushDowngradeOutperform ➝ Neutral$20.00 ➝ $5.00
12/8/2023JPMorgan Chase & Co.Initiated CoverageOverweight$18.00
12/5/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
11/27/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
9/19/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
9/5/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
8/30/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00
8/9/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00
8/8/2023WedbushReiterated RatingOutperform$20.00
6/8/2023HC WainwrightLower Target$28.00 ➝ $27.00
4/27/2023Robert W. BairdInitiated CoverageOutperform$20.00
4/19/2023Needham & Company LLCReiterated RatingBuy$23.00
3/27/2023HC WainwrightReiterated RatingBuy
3/15/2023GuggenheimReiterated RatingBuy$26.00
3/15/2023Needham & Company LLCLower TargetBuy$24.00 ➝ $23.00
1/5/2023Leerink PartnersBoost TargetOutperform$18.00 ➝ $20.00
12/14/2022Needham & Company LLCInitiated CoverageBuy$24.00
12/13/2022GuggenheimBoost TargetBuy$22.00 ➝ $24.00
11/17/2022Leerink PartnersLower TargetOutperform$20.00 ➝ $18.00
11/16/2022WedbushLower Target$19.00
8/15/2022GuggenheimBoost Target$18.00
6/28/2022GuggenheimInitiated CoverageBuy$15.00
6/10/2022Leerink PartnersBoost TargetOutperform$14.00 ➝ $15.00
11/14/2021Leerink PartnersInitiated CoverageBuy$20.00
11/5/2021HC WainwrightBoost TargetBuy$25.00 ➝ $31.00
10/11/2021HC WainwrightInitiated CoverageBuy$25.00
1/4/2021Lifesci CapitalReiterated RatingOutperform
12/23/2020Piper SandlerInitiated CoverageOverweight$22.00 ➝ $22.00
12/16/2020Leerink PartnersInitiated CoverageOutperform$20.00
11/10/2020WedbushBoost TargetOutperform$6.00 ➝ $24.00
10/14/2020LADENBURG THALM/SH SHInitiated CoverageBuy$4.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 7 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 6 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 6 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Cogent Biosciences logo
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $9.08
Low: $8.93
High: $9.30

50 Day Range

MA: $10.89
Low: $8.90
High: $12.30

52 Week Range

Now: $9.08
Low: $3.67
High: $12.61

Volume

1,934,643 shs

Average Volume

1,434,011 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Cogent Biosciences?

The following sell-side analysts have issued research reports on Cogent Biosciences in the last twelve months: Citigroup Inc., HC Wainwright, JPMorgan Chase & Co., Leerink Partnrs, Needham & Company LLC, Robert W. Baird, and Wedbush.
View the latest analyst ratings for COGT.

What is the current price target for Cogent Biosciences?

0 Wall Street analysts have set twelve-month price targets for Cogent Biosciences in the last year. Their average twelve-month price target is $14.83, suggesting a possible upside of 63.4%. JPMorgan Chase & Co. has the highest price target set, predicting COGT will reach $21.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $10.00 for Cogent Biosciences in the next year.
View the latest price targets for COGT.

What is the current consensus analyst rating for Cogent Biosciences?

Cogent Biosciences currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for COGT.

What other companies compete with Cogent Biosciences?

Other companies that are similar to Cogent Biosciences include Enlivex Therapeutics, Immunovant, Organon & Co., Rhythm Pharmaceuticals and Apellis Pharmaceuticals. Learn More about companies similar to Cogent Biosciences.

How do I contact Cogent Biosciences' investor relations team?

Cogent Biosciences' physical mailing address is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. The technology company's listed phone number is (617) 945-5576 and its investor relations email address is [email protected]. The official website for Cogent Biosciences is www.cogint.com. Learn More about contacing Cogent Biosciences investor relations.